PhysioWave Provides Pulse Wave Velocity Measurements for DARPA's Measuring Biological Aptitude Program

MENLO PARK, Calif., December 18, 2020 (Newswire.com) - ​​PhysioWave, Inc., a developer of advanced cardiovascular risk assessment instruments, participated in the inaugural human trial within the ambitious Defense Advanced Research Projects Agency (DARPA) Measuring Biological Aptitude (MBA) program. The DARPA MBA program aims to understand the underlying biological processes that govern warfighters' performance. Within the PEERLESS project, a multidisciplinary team of researchers from across the country seek to measure biologic aptitude – as well as stress response and resiliency – by rigorously assessing physical, physiological, cognitive, behavioral and team phenotypes in military cohorts during stressful training events and connecting them to underlying molecular “expression circuits”.

Pulse Wave Velocity (PWV) is a measure of arterial stiffness and is mostly known as a clinically-validated biomarker for the detection of cardiovascular (CV) risk, independent of other risk factors such as blood pressure. However, extensive research has been conducted on the effects of training and physical exercise on arterial stiffness, and as such, PWV is of particular interest as a possible factor indicative of warfighter physical fitness, physiological potential, and hydration status.

PhysioWave has developed an arterial pulse sensing technology that is designed to provide PWV measurements in less than a minute, without disrupting training activities or workflow in the clinical setting. The technology is backed by an extensive patent portfolio and has been integrated in the PhysioWave Pro™ device – the only FDA-cleared scale-format PWV device available.

“Using PhysioWave PWV technology in this project was a natural choice as is it is the only technology suitable for a fast-paced field study and supported by a FDA-cleared device,” said Dr. Tim Broderick, the PEERLESS team lead from the Institute for Human & Machine Cognition (IHMC, Pensacola, Florida).

The first round of measurements was made during a United States Air Force training event at Joint Base San Antonio Bullis in October 2020. As part of extensive data collection within the IRB approved PEERLESS study, participants had their PWV measured at rest and after exercise on a research version of the PWV scale. In the upcoming months, this data will be integrated into performance models developed by the PEERLESS team. The next rounds of measurements are scheduled for early next year.

About PhysioWave

PhysioWave was founded by a group of Stanford researchers who realized that one of the most meaningful measures of cardiovascular health, Pulse Wave Velocity (PWV), was not in widespread use because it was difficult to obtain. They invented a way to measure PWV in under a minute while a patient is being weighed, with no change to clinical workflow. Realizing the potential of this technology to identify individuals at high risk of cardiovascular disease, the company developed a clinical product, with a clinically valid home version to follow. For further information, visit www.physiowave.com

Media Contact:       Laurent Giovangrandi

info@physiowave.com

Cautionary Disclaimer Statement

This news release contains forward-looking statements relating statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of PhysioWave. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and PhysioWave will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Source: Physiowave